Drug Trial Radar · NCT06921850
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
43
Actual
Start
Apr 7, 2025
Primary completion
Dec 21, 2026
Study completion Mar 6, 2029
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Apr 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 9 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
Conditions
- Hidradenitis Suppurativa
Interventions
BimekizumabDrug
Bimekizumab will be administered at pre-specified timepoints.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Plasma bimekizumab concentrations at Week 16Time frame: At Week 16
Locations
16 sites in 3 countries. Site status is shown where the registry gives one.
Hs0006 50708
Roseville, California
Hs0006 50684
Sacramento, California
Hs0006 50707
Washington D.C., District of Columbia
Hs0006 50199
Miami, Florida
Hs0006 50712
Bowling Green, Kentucky
Hs0006 50178
Clarkston, Michigan
Hs0006 50710
Fort Gratiot, Michigan
Hs0006 50711
Troy, Michigan
Hs0006 50706
Chapel Hill, North Carolina
Hs0006 50202
Fairborn, Ohio
Hs0006 50201
Arlington, Texas
Hs0006 40326
Berlin, Germany
Hs0006 40625
Lodz, Poland
Hs0006 40761
Warsaw, Poland
Hs0006 40095
Wroclaw, Poland
Hs0006 40845
Wroclaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.